These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 23291248)

  • 1. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease.
    Taylor JM; Main BS; Crack PJ
    Neurochem Int; 2013 Apr; 62(5):803-19. PubMed ID: 23291248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease.
    Sun F; Kanthasamy A; Anantharam V; Kanthasamy AG
    Pharmacol Ther; 2007 Jun; 114(3):327-44. PubMed ID: 17521740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal pathology in Parkinson's disease.
    Schulz JB; Falkenburger BH
    Cell Tissue Res; 2004 Oct; 318(1):135-47. PubMed ID: 15365812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anti-inflammatory therapy for Parkinson's disease.
    Gao HM; Liu B; Zhang W; Hong JS
    Trends Pharmacol Sci; 2003 Aug; 24(8):395-401. PubMed ID: 12915048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of Parkinson's disease.
    Sherer TB; Betarbet R; Greenamyre JT
    Curr Opin Investig Drugs; 2001 May; 2(5):657-62. PubMed ID: 11569943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroinflammation in Parkinson's disease.
    Hirsch EC; Vyas S; Hunot S
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S210-2. PubMed ID: 22166438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?
    Bisaglia M; Filograna R; Beltramini M; Bubacco L
    Ageing Res Rev; 2014 Jan; 13():107-14. PubMed ID: 24389159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.
    Xiong N; Long X; Xiong J; Jia M; Chen C; Huang J; Ghoorah D; Kong X; Lin Z; Wang T
    Crit Rev Toxicol; 2012 Aug; 42(7):613-32. PubMed ID: 22574684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of specific dopaminergic neuronal death in Parkinson's disease].
    Ogawa N; Asanuma M; Miyoshi K
    Nihon Rinsho; 2004 Sep; 62(9):1629-34. PubMed ID: 15462376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease?
    Michel PP; Ruberg M; Hirsch E
    Sci STKE; 2006 Apr; 2006(332):pe19. PubMed ID: 16639033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
    Maguire-Zeiss KA; Short DW; Federoff HJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
    Hald A; Lotharius J
    Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review).
    Guo JD; Zhao X; Li Y; Li GR; Liu XL
    Int J Mol Med; 2018 Apr; 41(4):1817-1825. PubMed ID: 29393357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.
    Schildknecht S; Gerding HR; Karreman C; Drescher M; Lashuel HA; Outeiro TF; Di Monte DA; Leist M
    J Neurochem; 2013 May; 125(4):491-511. PubMed ID: 23452040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of iron in the pathogenesis of Parkinson's disease.
    Sian-Hülsmann J; Mandel S; Youdim MB; Riederer P
    J Neurochem; 2011 Sep; 118(6):939-57. PubMed ID: 21138437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease.
    Calì T; Ottolini D; Brini M
    Biofactors; 2011; 37(3):228-40. PubMed ID: 21674642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.
    Collins LM; Toulouse A; Connor TJ; Nolan YM
    Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.